4. Primary lateral sclerosis Disease details / Clinical trials / Drug dev / DR info
Clinical trials : 5 / Drugs : 13 - (DrugBank : 6) / Drug target genes : 13 - Drug target pathways : 25
Drugs and their primary sponsors and trial info
Carbidopa-levodopa
Washington University School of Medicine
2019 Phase 1 NCT03929068 United States;
Dalfampridine
Weill Medical College of Cornell University
2016 Phase 1 NCT02868567 United States;
Daraprim
Weill Medical College of Cornell University
2013 - EUCTR2011-004798-99-DE Germany;Italy;United States;
Dexdor
Turku University Hospital
2018 Phase 4 EUCTR2018-000142-18-FI Finland;
HB-adMSCs
Hope Biosciences Stem Cell Research Foundation
2021 - NCT04825613 United States;
Ketanest-S
Turku University Hospital
2018 Phase 4 EUCTR2018-000142-18-FI Finland;
Levetiracetam
Duke University
2006 Phase 2 NCT00324454 United States;
Stem Cells
Stem Cells Arabia
2016 Phase 1/Phase 2 NCT03067857 -
Washington University School of Medicine
2019 Phase 1 NCT03929068 United States;
Dalfampridine
Weill Medical College of Cornell University
2016 Phase 1 NCT02868567 United States;
Daraprim
Weill Medical College of Cornell University
2013 - EUCTR2011-004798-99-DE Germany;Italy;United States;
Dexdor
Turku University Hospital
2018 Phase 4 EUCTR2018-000142-18-FI Finland;
HB-adMSCs
Hope Biosciences Stem Cell Research Foundation
2021 - NCT04825613 United States;
Ketanest-S
Turku University Hospital
2018 Phase 4 EUCTR2018-000142-18-FI Finland;
Levetiracetam
Duke University
2006 Phase 2 NCT00324454 United States;
Stem Cells
Stem Cells Arabia
2016 Phase 1/Phase 2 NCT03067857 -